Free Trial

Enliven Therapeutics (NASDAQ:ELVN) Trading 6.1% Higher - Here's Why

Enliven Therapeutics logo with Medical background

Key Points

  • Enliven Therapeutics' stock rose by 6.1%, trading at $21.55 after previously closing at $20.32, although the trading volume was significantly lower than average.
  • Analyst ratings reflect a Moderate Buy consensus with a price target average of $41.20, with Robert W. Baird set a new target of $52.00 and Goldman Sachs providing a buy rating at a target of $37.00.
  • Insider trading activity included significant sales by CEO Samuel Kintz and COO Anish Patel, resulting in a decrease of their ownership stakes in the company.
  • Five stocks we like better than Enliven Therapeutics.

Enliven Therapeutics, Inc. (NASDAQ:ELVN - Get Free Report) shares traded up 6.1% on Thursday . The stock traded as high as $21.19 and last traded at $21.55. 75,183 shares changed hands during mid-day trading, a decline of 81% from the average session volume of 395,298 shares. The stock had previously closed at $20.32.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on the stock. Robert W. Baird boosted their price target on shares of Enliven Therapeutics from $40.00 to $52.00 and gave the stock an "outperform" rating in a research report on Monday, June 16th. Weiss Ratings restated a "sell (d-)" rating on shares of Enliven Therapeutics in a research report on Wednesday. The Goldman Sachs Group assumed coverage on shares of Enliven Therapeutics in a research report on Monday, June 16th. They issued a "buy" rating and a $37.00 price target on the stock. Finally, HC Wainwright boosted their price target on shares of Enliven Therapeutics from $40.00 to $48.00 and gave the stock a "buy" rating in a research report on Wednesday, July 2nd. Five investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $41.20.

Read Our Latest Analysis on ELVN

Enliven Therapeutics Stock Performance

The stock's 50 day moving average price is $19.69 and its 200-day moving average price is $19.57.

Enliven Therapeutics (NASDAQ:ELVN - Get Free Report) last issued its earnings results on Wednesday, August 13th. The company reported ($0.49) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.53) by $0.04. As a group, sell-side analysts predict that Enliven Therapeutics, Inc. will post -1.95 EPS for the current fiscal year.

Insider Activity at Enliven Therapeutics

In related news, CEO Samuel Kintz sold 3,700 shares of the company's stock in a transaction dated Friday, September 26th. The shares were sold at an average price of $20.06, for a total value of $74,222.00. Following the completion of the sale, the chief executive officer directly owned 915,392 shares of the company's stock, valued at $18,362,763.52. This represents a 0.40% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, COO Anish Patel sold 6,667 shares of the stock in a transaction dated Tuesday, October 7th. The shares were sold at an average price of $20.10, for a total transaction of $134,006.70. Following the sale, the chief operating officer directly owned 276,641 shares of the company's stock, valued at approximately $5,560,484.10. The trade was a 2.35% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 103,234 shares of company stock valued at $2,111,344 over the last ninety days. Company insiders own 25.90% of the company's stock.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the stock. Goldman Sachs Group Inc. raised its position in shares of Enliven Therapeutics by 61.3% during the 1st quarter. Goldman Sachs Group Inc. now owns 211,752 shares of the company's stock worth $4,167,000 after purchasing an additional 80,506 shares during the last quarter. Rhumbline Advisers lifted its holdings in Enliven Therapeutics by 4.9% in the 1st quarter. Rhumbline Advisers now owns 52,502 shares of the company's stock valued at $1,033,000 after purchasing an additional 2,466 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its holdings in Enliven Therapeutics by 67.1% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 43,714 shares of the company's stock valued at $984,000 after purchasing an additional 17,546 shares in the last quarter. Wellington Management Group LLP lifted its holdings in Enliven Therapeutics by 4.7% in the 1st quarter. Wellington Management Group LLP now owns 84,700 shares of the company's stock valued at $1,667,000 after purchasing an additional 3,784 shares in the last quarter. Finally, GAMMA Investing LLC lifted its holdings in Enliven Therapeutics by 3,058.1% in the 1st quarter. GAMMA Investing LLC now owns 2,716 shares of the company's stock valued at $53,000 after purchasing an additional 2,630 shares in the last quarter. Institutional investors and hedge funds own 95.08% of the company's stock.

About Enliven Therapeutics

(Get Free Report)

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.

Featured Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Enliven Therapeutics Right Now?

Before you consider Enliven Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Enliven Therapeutics wasn't on the list.

While Enliven Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report
Like this article? Share it with a colleague.